Table 3 Results for the direct head-to-head random effects meta-analysis and network meta-analysis
Comparison | Difference in mean stool frequency (direct) | Lower credible limit (direct) | Upper credible limit (direct) | Tau-sq: between study heterogeneity for direct MA | Number of data sets for direct MA | Difference in mean stool frequency (NMA) | Lower credible limit (NMA) | Upper credible limit (NMA) | Probability active treatment is better than comparator in NMAa |
|---|---|---|---|---|---|---|---|---|---|
PEG vs Placebo | 1.8 | 0.2 | 3.6 | 2.17 | 10 | 1.8 | 1.0 | 2.8 | 100.0 % |
PEG + E vs Placebo | 2.1 | −0.1 | 4.1 | 2.09 | 6 | 1.9 | 0.9 | 3.0 | 100.0 % |
PEG + E vs PEG | −0.5 | −4.5 | 3.3 | 2.81 | 3 | 0.1 | −1.1 | 1.2 | 58.5 % |
PEG vs Lactulose | 1.8 | 0.0 | 3.5 | 97.6 % | |||||
PEG + E vs Lactulose | 1.7 | −4.2 | 4.9 | 3.45 | 2 | 1.9 | 0.2 | 3.6 | 98.6 % |
PEG vs Serotonin agonist | 1.3 | −1.0 | 3.5 | 87.7 % | |||||
PEG + E vs Serotonin agonist | 1.4 | −0.9 | 3.7 | 89.2 % | |||||
PEG vs Bulk forming | 2.6 | −0.8 | 5.8 | 93.6 % | |||||
PEG + E vs Bulk forming | 2.6 | −0.5 | 5.8 | 95.1 % |